As of June 06, 2026, Biocryst Pharmaceuticals's top three insider holders are Jon P Stonehouse (Chief Executive Officer, 1.32Mn shares), Charles K Gayer (President And Cco, 952.58K shares), Alane P Barnes (Chief Legal Officer, 400.70K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Steve Aselage | - | 70,159 | 0 | 14 Jun, 2024 |
| Nancy J Hutson | - | 99,138 | 0 | 16 Jun, 2025 |
| Jon P Stonehouse | Chief Executive Officer | 1,323,850 | 0 | 03 Mar, 2026 |
| William P Sheridan | Chief Medical Officer | 37,954 | 0 | 14 Mar, 2022 |
| Yarlagadda S Babu | Chief Discovery Officer | 298,541 | 0 | 16 Nov, 2022 |
| George B Abercrombie | - | 36,431 | 0 | 14 Jun, 2024 |
| Steven Frank | - | 18,903 | 0 | 03 Mar, 2026 |
| Alane P Barnes | Chief Legal Officer | 400,703 | 0 | 18 Mar, 2026 |
| Helen M. Thackray | Chief Rd Officer | 377,318 | 0 | 02 Apr, 2025 |
| Jill C. Milne | - | 15,382 | 0 | 03 Mar, 2026 |
| Machelle Sanders | - | 30,642 | 0 | 17 Nov, 2025 |
| Theresa Heggie | - | 65,352 | 0 | 24 Mar, 2026 |
| Michael L Jones | Exec. Director, Finance Pao | 16,653 | 0 | 21 Dec, 2022 |
| Charles K Gayer | President And Cco | 952,583 | 0 | 23 Dec, 2025 |
| Anthony Doyle | Chief Financial Officer | 377,867 | 0 | 23 Dec, 2024 |
| Amy E Mckee | - | 42,432 | 0 | 03 Mar, 2026 |
| Babar Ghias | Chief Financial Officer | 268,700 | 0 | 19 Dec, 2025 |
| Sandeep Menon | Chief Rd Officer | 205,150 | 0 | 07 Apr, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 06 Apr, 2026 | Sandeep Menon | Common Stock | A | 205,150 | $0.00 | 205,150 | D | A |
| 06 Apr, 2026 | Sandeep Menon | Emp. Stock Option (Right to Buy) | A | 441,350 | $0.00 | 441,350 | D | A |
| 20 Mar, 2026 | Theresa Heggie | Common Stock | A | 49,933 | $6.30 | 115,285 | D | M |
| 20 Mar, 2026 | Theresa Heggie | Common Stock | A | 49,933 | $6.30 | 115,285 | D | M |
| 20 Mar, 2026 | Theresa Heggie | Common Stock | A | 49,933 | $6.30 | 115,285 | D | M |
| 20 Mar, 2026 | Theresa Heggie | Common Stock | D | 49,933 | $10.11 | 65,352 | D | S |
| 20 Mar, 2026 | Theresa Heggie | Common Stock | D | 49,933 | $10.11 | 65,352 | D | S |
| 20 Mar, 2026 | Theresa Heggie | Common Stock | D | 49,933 | $10.11 | 65,352 | D | S |
| 20 Mar, 2026 | Theresa Heggie | Automatic Stock Option Grant | D | 49,933 | $0.00 | 0 | D | M |
| 20 Mar, 2026 | Theresa Heggie | Automatic Stock Option Grant | D | 49,933 | $0.00 | 0 | D | M |
| 20 Mar, 2026 | Theresa Heggie | Automatic Stock Option Grant | D | 49,933 | $0.00 | 0 | D | M |
| 16 Mar, 2026 | Alane P Barnes | Common Stock | A | 150,000 | $5.51 | 550,703 | D | M |
| 16 Mar, 2026 | Alane P Barnes | Common Stock | A | 150,000 | $5.51 | 550,703 | D | M |
| 16 Mar, 2026 | Alane P Barnes | Common Stock | A | 150,000 | $5.51 | 550,703 | D | M |
| 16 Mar, 2026 | Alane P Barnes | Common Stock | D | 150,000 | $9.15 | 400,703 | D | S |
| 16 Mar, 2026 | Alane P Barnes | Common Stock | D | 150,000 | $9.15 | 400,703 | D | S |
| 16 Mar, 2026 | Alane P Barnes | Common Stock | D | 150,000 | $9.15 | 400,703 | D | S |
| 16 Mar, 2026 | Alane P Barnes | Emp. Stock Option (Right to Buy) | D | 150,000 | $0.00 | 0 | D | M |
| 16 Mar, 2026 | Alane P Barnes | Emp. Stock Option (Right to Buy) | D | 150,000 | $0.00 | 0 | D | M |
| 16 Mar, 2026 | Alane P Barnes | Emp. Stock Option (Right to Buy) | D | 150,000 | $0.00 | 0 | D | M |